Author:
Parit Swapnali,Manchare Ajit,Gholap Amol D.,Mundhe Prashant,Hatvate Navnath,Rojekar Satish,Patravale Vandana
Reference224 articles.
1. A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521, (n.d.). https://clinicaltrials.gov/study/NCT05323045?intr=BYON3521&rank=1.
2. Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes;Abdollahpour-Alitappeh;J. Cell. Physiol.,2019
3. Mechanisms of Resistance to Antibody-Drug Conjugates;Abelman;Cancers (basel).,2023
4. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape;Adams;ESMO Open,2021
5. ADC Approval up to 2023, BroadPharm (n.d.). https://broadpharm.com/blog/ADC-Approval-up-to-2023 (accessed April 1, 2024).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献